Historical News

Taipei, Taiwan, 27 August 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a leading global pharmaceutical company, today announced that it has received the Gold Award in the Social Inclusion category at the 2026 Taiwan Sust...

Taipei, Taiwan and Morristown, N.J., 26 August 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a leading global pharmaceutical company, today announced that Norwich Pharmaceuticals, Inc. (“Norwich”), a wholly ow...

Taipei, Taiwan, 21 August 2026 — Lotus Pharmaceutical Co., Ltd. (“Lotus”, TWSE Stock Code: 1795), a leading multinational pharmaceutical company, today announced a strategic licensing and commercialization agreement with Alvotech (N...

Taipei, Taiwan, 19 August 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a leading global pharmaceutical company, today announced that its generic version of POMALYST® (pomalidomide) capsules, in 1 mg, 2 mg, 3 mg and 4...

Taipei, Taiwan, 18 August 2026 — Lotus Pharmaceutical Co., Ltd. (“Lotus”, TWSE Stock Code: 1795), a leading multinational pharmaceutical company, proudly announces that it has been named a recipient of the HR Asia Best Companies to ...

Taipei, Taiwan, 13 Aug 2026 — Lotus Pharmaceutical (1795:TT; “Lotus” or “the Company”), a multinational pharmaceutical company, announced its financial results for the first half and second quarter ended 30 June 2026, se...

Taipei, Taiwan, 10 August 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a global pharmaceutical leader based in Taiwan, today announced its unaudited consolidated revenue for July 2026 of NT$2,492 million, representi...

Taipei, Taiwan and Seoul, South Korea, 29 July 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795, “Lotus” or the “Company”), a global pharmaceutical company headquartered in Taiwan, today announced that ...

Taipei, Taiwan, 15 July 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a leading global pharmaceutical company, today announced that the United States Food and Drug Administration ("US FDA") has accepted for substantive re...